KR20220163986A - 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법 - Google Patents

브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법 Download PDF

Info

Publication number
KR20220163986A
KR20220163986A KR1020227037384A KR20227037384A KR20220163986A KR 20220163986 A KR20220163986 A KR 20220163986A KR 1020227037384 A KR1020227037384 A KR 1020227037384A KR 20227037384 A KR20227037384 A KR 20227037384A KR 20220163986 A KR20220163986 A KR 20220163986A
Authority
KR
South Korea
Prior art keywords
subject
pharmaceutically acceptable
acceptable salt
fenebbrutinib
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227037384A
Other languages
English (en)
Korean (ko)
Inventor
히데키 가렌
에드몬드 후아텅 텡
아우렐리엔 비아코쯔
한스-크리스티안 폰 뷔딘겐
Original Assignee
제넨테크, 인크.
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크., 에프. 호프만-라 로슈 아게 filed Critical 제넨테크, 인크.
Publication of KR20220163986A publication Critical patent/KR20220163986A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227037384A 2020-04-03 2021-04-01 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법 Pending KR20220163986A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005095P 2020-04-03 2020-04-03
US63/005,095 2020-04-03
US202063051767P 2020-07-14 2020-07-14
US63/051,767 2020-07-14
PCT/US2021/025301 WO2021202825A1 (en) 2020-04-03 2021-04-01 Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
KR20220163986A true KR20220163986A (ko) 2022-12-12

Family

ID=75625678

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037384A Pending KR20220163986A (ko) 2020-04-03 2021-04-01 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법

Country Status (13)

Country Link
US (1) US12605376B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125906A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520469A (cg-RX-API-DMAC7.html)
KR (1) KR20220163986A (cg-RX-API-DMAC7.html)
CN (1) CN115916205A (cg-RX-API-DMAC7.html)
AU (1) AU2021249129B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177390A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002699A1 (cg-RX-API-DMAC7.html)
IL (1) IL296990A (cg-RX-API-DMAC7.html)
MX (1) MX2022012310A (cg-RX-API-DMAC7.html)
TW (1) TWI907406B (cg-RX-API-DMAC7.html)
WO (1) WO2021202825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899163B (zh) * 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
BR112023021235A2 (pt) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途
WO2024238524A1 (en) * 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
US20210113568A1 (en) * 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
EP3914250A1 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
TWI899163B (zh) 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法

Also Published As

Publication number Publication date
BR112022019846A2 (pt) 2022-11-22
TW202203925A (zh) 2022-02-01
IL296990A (en) 2022-12-01
AU2021249129B2 (en) 2026-06-04
JP2023520469A (ja) 2023-05-17
CN115916205A (zh) 2023-04-04
US12605376B2 (en) 2026-04-21
TWI907406B (zh) 2025-12-11
EP4125906A1 (en) 2023-02-08
AU2021249129A1 (en) 2022-10-20
CL2022002699A1 (es) 2023-03-31
WO2021202825A1 (en) 2021-10-07
CA3177390A1 (en) 2021-10-07
US20230149395A1 (en) 2023-05-18
MX2022012310A (es) 2022-10-27

Similar Documents

Publication Publication Date Title
US12605376B2 (en) Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase
JP2026082835A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法
TW201804997A (zh) 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
US20180064702A1 (en) Treatment of progressive forms of multiple sclerosis with laquinimod
KR20240004451A (ko) Ilt7 결합 단백질을 이용한 자가면역 장애의 치료 방법
IL324175A (en) Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
CN112437665A (zh) 用于治疗及预防多发性硬化症的方法中的经取代氨基-嘧啶化合物
TW202517276A (zh) 用於治療自體免疫及發炎疾病之rip1激酶抑制劑之調配物及劑量療法
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
RU2858695C2 (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
EP4634225A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
HK40087403A (en) Methods of treating relapsing multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
RU2824354C2 (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
TW202210068A (zh) 用於治療家族性地中海型發熱病的cxcr-2抑制劑
JP2025535457A (ja) 原発性膜性腎症を治療するための方法
Large Clinical Study Protocol

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000